Page 14 - AN-4-3

Advanced Neurology Stem cell therapy in stroke treatment: Advances and prospects

Figure 3. Stem cell therapy in stroke

Figure 4. Mechanism of action of stem cell therapy in stroke
blind, controlled study, which was based on the findings activity from the brain to the extremities as mentioned.
76
of a preclinical investigation employing peripheral blood According to other findings, intravenous administration
stem cells (PBSCs). Before stereotaxic transplantation of of BM-MNCs is both beneficial and safe. A single-arm
immunoselected PBSCs included in the trial, patients who Phase I trial employing autologous BM-MNCs in acute
fulfilled the study eligibility criteria received granulocyte- ischemic stroke showed promise as a novel experimental
colony stimulating factor (G-CSF) subcutaneous injections approach that could assist extend the therapeutic window
for five consecutive days. Neither the study method nor for ischemic stroke patients. No adverse events (AEs) were
75
the follow-up caused any adverse events. Clinical outcomes discovered following transplantation. 77,78 NSI-566 primary
were assessed by tracking changes based on NIHSS, ESS, adherent neural cells, isolated from a human fetal spinal
EMS, and MAR scores from baseline to 12 months in cord, were tested for safety and durability in a Phase I trial
both the PBSC-treated and control groups. This study at a second site. The effectiveness of implanting human
also provided significant evidence that PBSCs are effective spinal cord-derived neural stem cells at three distinct
in reversing stroke-related motor deficits, remodeling doses into the peri-infarct region of stable stroke patients
the injured corticospinal tract (CST), and restoring was demonstrated in a patient cohort study. The bulk of

Volume 4 Issue 3 (2025) 8 doi: 10.36922/an.5582